PDF
ePub
Citation
Print
Abstract
Background
It is well known that kidney transplant recipients in Western countries are at high risk for development of lower extremity (LE) deep vein thrombosis (DVT). The aim of this study was to establish the frequency of symptomatic LE DVT, the time until their occurrence, and to define risk factors for them following kidney transplantation (KT) in Korea.
Methods
We performed a retrospective analysis of LE DVT among 1695 patients who were kidney transplant recipients between 1969 and 2009. All patients were symptomatic with objective diagnostic modalities. Results were compared with those for a cohort of kidney transplant recipients from the same center without DVT.
Results
During follow-up, 21 symptomatic LE DVTs (1.2%) occurred in 18 patients (1.1%). The mean interval between transplantation and a first episode of DVT was 77.1±76.6 months. No DVT episode developed within one month after KT. There were no significant differences in body mass index, graft function, donor age and sex, recipient sex, type of preoperative renal replacement therapy, immunosuppressive agents, and malignancy between the two groups. Patients who developed LE DVT had a significantly different recipient age, presence of diabetes mellitus, presence of acute rejection episodes, and type of donor (P＜0.05).
Conclusions
Our retrospective study showed that the incidence of LE symptomatic DVT after KT is lower than after other surgeries performed in Korean hospitals and after KT performed in Western countries. There were no cases of symptomatic DVT within 1 month after KT. Our findings suggest that aggressive DVT prevention is not necessary for KT recipients in Korea.
References
1). Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th Ed. Chest. 2008; 133(6S):381–453.
2). Irish AB, Green FR. Environmental and genetic determinants of the hypercoagulable state and cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant. 1997; 12:167–73.
3). Ramirez PJ, Gohh RY, Kestin A, Monaco AP, Morrissey PE. Renal allograft loss due to proximal extension of ileo-femoral deep venous thrombosis. Clin Transplant. 2002; 16:310–3.
4). Butt KM, Rao TK, Friedman EA, Kountz SL. Venous complications of renal transplantation. Proc Clin Dial Transplant Forum. 1975; 5:77–80.
5). Joffe SN. Deep vein thrombosis after renal transplantation. Vasc Surg. 1976; 10:134–7.
6). Venkateswara K, Smith EJ, Alexander JW, Fidler JP, Pemmaraju SR, Pollack VE. Thromboembolic disease in renal allograft recipients. What is its clinical significance? Arch Surg. 1976; 111:1086–92.
7). Arnadottir M, Bergentz SE, Bergqvist D, Husberg B, Konrad P, Lindholm T. Thromboembolic complications after renal transplantation: a retrospective analysis. World J Surg. 1983; 7:757–61.
8). Bergqvist D, Bergentz SE, Bornmyr S, Husberg B, Konrad P, Ljungnér H. Deep vein thrombosis after renal transplantation: a prospective analysis of frequency and risk factors. Eur Surg Res. 1985; 17:69–74.
9). Vanrenterghem Y, Roels L, Lerut T, Gruwez J, Michielsen P, Gresele P, et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet. 1985; 1:999–1002.
10). Allen RD, Michie CA, Murie JA, Morris PJ. Deep venous thrombosis after renal transplantation. Surg Gynecol Obstet. 1987; 164:137–42.
11). Gruber SA, Pescovitz MD, Simmons RL, Najarian JS, Ascher NL, Payne WD, et al. Thromboembolic complications in renal allograft recipients. A report from the prospective randomized study of cyclosporine versus aza-thioprine-antilymphocyte globulin. Transplantation. 1987; 44:775–8.
12). Vachharajani TJ, Asari AJ, Tucker B, Baker LR. Ipsilateral deep venous thrombosis in renal transplant recipients: the need for prolonged anticoagulation. Nephrol Dial Transplant. 1997; 12:627–8.
13). Humar A, Johnson EM, Gillingham KJ, Sutherland DE, Payne WD, Dunn DL, et al. Venous thromboembolic complications after kidney and kidney-pancreas transplantation: a multivariate analysis. Transplantation. 1998; 65:229–34.
14). Poli D, Zanazzi M, Antonucci E, Bertoni E, Salvadori M, Abbate R, et al. Renal transplant recipients are at high risk for both symptomatic and asymptomatic deep vein thrombosis. J Thromb Haemost. 2006; 4:988–92.
15). Derweesh IH, Ismail HR, Goldfarb DA, Araki M, Zhou L, Modlin C, et al. Intraoperative placing of drains decreases the incidence of lymphocele and deep vein thrombosis after renal transplantation. BJU Int. 2008; 101:1415–9.
16). Park WI, Hahn JS, Kim CY, Jang JH, Lee ST, Min YH, et al. Venous thrombosis after renal transplantation. Korean J Hemost Thromb. 2000; 7:41–6.
17). Haines ST. Venous thromboembolism: pathophysiology and clinical presentation. Am J Health Syst Pharm. 2003; 60:S3–5.
18). Brunkwall J, Bergqvist D, Bergentz SE, Bornmyr S, Husberg B. Postoperative deep venous thrombosis after renal transplantation. Effects of cyclosporine. Transplantation. 1987; 43:647–9.
19). Joffe SN. The incidence of postoperative deep vein thrombosis. Thromb Res. 1975; 7:141–8.
20). Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The longterm clinical course of acute deep venous thrombosis. Ann Intern Med. 1996; 125:1–7.
21). Poli D, Zanazzi M, Antonucci E, Marcucci R, Rosati A, Bertoni E, et al. High rate of recurrence in renal transplant recipients after a first episode of venous thromboembolism. Transplantation. 2005; 80:789–93.
22). Von Kaulla KN, Von Kaulla E, Wasantapruck S, Marchioro TL, Starzl TE. Blood coagulation in uremic patients before and after hemodialysis and transplantation of the kidney. Arch Surg. 1966; 92:184–91.
23). Ljungqvist U, Bergentz SE, Leandoer L, Nilsson IM. Coagulation and fibrinolysis after renal transplantation. Scand J Urol Nephrol. 1969; 3:23–9.
24). Merkus JW, Barendregt WB, van Asten WN, van Langen H, Hoitsma AJ, van der Vliet JA. Changes in venous hemodynamics after renal transplantation. Transpl Int. 1998; 11:284–7.
25). Movat HZ, Mustard JF, Taichman NS, Uriuhara T. Platelet aggregation and release of ADP, serotonin and histamine associated with phagocytosis of antigen-antibody complexes. Proc Soc Exp Biol Med. 1965; 120:232–7.
26). Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost. 1999; 82:610–9.
27). Kim IG, Kim KH, Seo HJ, Kim JI, Ahn CH, Kim JS, et al. Deep vein thrombosis after surgery for gastrointestinal cancer-incidence and correlation with risk factors-. J Korean Soc Vasc Surg. 2004; 20:237–41.
28). Yun SS, Choi SH, Kim SD, Cho HJ, Park SC, Kim KH, et al. The risk factors for pulmonary embolism in patients with lower extremity deep vein thrombosis. J Korean Soc Vasc Surg. 2008; 24:119–24.
29). Hamlin CR, Kohn RR, Luschin JH. Apparent accelerated aging of human collagen in diabetes mellitus. Diabetes. 1975; 24:902–4.
30). Kobayashi M, Yorioka N, Yamakido M. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis. Nephron. 1997; 76:56–61.
Table 1.
Characteristics of patients investigated
Table 2.
Treatment methods and results of deep vein thrombosis
Table 3.
Summary of reported series of lower extremity deep vein thrombosis in renal transplant recipients
XML Download